{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    41,
    43,
    48,
    50,
    51,
    52,
    53,
    129,
    55,
    57,
    62,
    64,
    65,
    66,
    67,
    72,
    75,
    77,
    84,
    86,
    91,
    92,
    94,
    95,
    122,
    124,
    125,
    126
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "Day 1 of Cycle 1",
        "anchorType": "CycleStart",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Cycle 1 Day 1"
      },
      {
        "id": "anchor_2",
        "definition": "surgery",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "surgery"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "Once Daily"
      },
      {
        "id": "rep_daily_2",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_22",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "QD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "BID"
      },
      {
        "id": "rep_cycle_1",
        "type": "Cycle",
        "cycleLength": "P21D",
        "sourceText": "21-day cycle"
      },
      {
        "id": "rep_cycle_15",
        "type": "Cycle",
        "sourceText": "Cycle 1 Day 1"
      },
      {
        "id": "rep_cycle_16",
        "type": "Cycle",
        "sourceText": "C1D5"
      },
      {
        "id": "rep_cycle_17",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until disease progression"
      },
      {
        "id": "rep_cycle_18",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until disease \nprogression"
      },
      {
        "id": "rep_cycle_22",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until unacceptable toxicity"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "-P2D",
        "endOffset": "P5D",
        "sourceText": "Days –2 through 5"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "startOffset": "P1D",
        "endOffset": "P21D",
        "sourceText": "Days 1 through 21"
      },
      {
        "id": "rep_window_4",
        "type": "Continuous",
        "startOffset": "-P2D",
        "endOffset": "P1D",
        "sourceText": "Days\n–2\n–1"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "sourceText": "Treatment Phase"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "7 days before"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "sourceText": "2 hours after"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "48 hours after"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "P42D",
        "minObservations": 2,
        "exitCondition": "uncontrolled adverse events or dose adjustment",
        "sourceText": "off-site phone visits every other cycle for subjects who have been receiving single-agent veliparib/placebo at a stable dose without adjustment for multiple cycles without uncontrolled adverse events"
      },
      {
        "id": "rep_llm_2",
        "type": "Interval",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "P63D",
        "minObservations": 1,
        "exitCondition": "disease progression",
        "sourceText": "Update tumor assessment schedule from every 9 weeks"
      },
      {
        "id": "rep_llm_3",
        "type": "Interval",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "P84D",
        "minObservations": 1,
        "exitCondition": "investigator's discretion (not to exceed 24 weeks)",
        "sourceText": "allow every 12 weeks (or at longer intervals not to exceed 24 weeks per the investigator's discretion) from the prior scan"
      },
      {
        "id": "rep_llm_4",
        "type": "Continuous",
        "startOffset": "-P28D",
        "endOffset": "P0D",
        "interval": "P28D",
        "minObservations": 1,
        "exitCondition": "Final Visit",
        "sourceText": "remove the requirement of tumor assessment at Final Visit in subjects without a tumor assessment within 4 weeks"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "crossover"
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "RANDOMIZATION",
          "TREATMENT_COMBINATION_PHASE",
          "TREATMENT_MONOTHERAPY_PHASE",
          "POST_TREATMENT_FOLLOW_UP",
          "SURVIVAL_FOLLOW_UP"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Day 1",
          "Tumor Assessment Every 9-12 Weeks",
          "Safety Follow-up",
          "Screening",
          "Final Visit",
          "Cycle 1 Day -2",
          "End of Study"
        ],
        "sourceText": "[{'condition': 'If subject discontinues carboplatin and paclitaxel without progression', 'path': ['VELIPARIB_PLACEBO_SINGLE_AGENT_MONOTHERAPY']}, {'condition': 'If subject discontinues all study drugs for reasons other than progression', 'path': ['ON_STUDY_OFF_DRUG_MONITORING', 'TUMOR_ASSESSMENT']}, {'condition': 'If subject randomized to placebo experiences PD', 'path': ['UNBLINDING', 'CROSSOVER_OPEN_LABEL_VELIPARIB_MONOTHERAPY']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Vital Sign",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Ecg",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "SINGLE signals: 4"
      },
      {
        "activityId": "Adverse Event",
        "executionType": "Single",
        "rationale": "SINGLE signals: 7"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1; RECURRING signals: 1"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Dosing",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Ct Scan",
        "executionType": "Recurring",
        "rationale": "EPISODE signals: 3; RECURRING signals: 6"
      },
      {
        "activityId": "Biopsy",
        "executionType": "Single",
        "rationale": "WINDOW signals: 1; SINGLE signals: 6"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Off-site phone visits",
        "executionType": "Single",
        "rationale": "Scheduled to occur every other cycle for subjects on stable doses of single-agent veliparib/placebo."
      },
      {
        "activityId": "Tumor assessment",
        "executionType": "Single",
        "rationale": "Scheduled at regular intervals (every 9 to 12 weeks, or up to 24 weeks) throughout the study."
      },
      {
        "activityId": "Hematologic blood counts for chemotherapy initiation",
        "executionType": "Single",
        "rationale": "Conditional workflow where chemotherapy begins based on specific blood count thresholds/guidelines."
      },
      {
        "activityId": "Adverse Event reporting (MDS, AML, or secondary primary malignancy)",
        "executionType": "Single",
        "rationale": "Continuous monitoring and reporting required over a specific time period, including delayed onset monitoring."
      },
      {
        "activityId": "Survival follow-up",
        "executionType": "Single",
        "rationale": "Repeated assessments for all subjects who have discontinued therapy to monitor survival status."
      },
      {
        "activityId": "Primary analysis unblinding",
        "executionType": "Single",
        "rationale": "A one-time event that occurred on 03 June 2019 for the sponsor."
      },
      {
        "activityId": "Local laboratory evaluations",
        "executionType": "Single",
        "rationale": "Scheduled safety monitoring performed at the site level throughout the study duration."
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutRequired": false,
      "sourceText": "crossover"
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "timing_at",
        "text": "a. If a subject discontinues paclitaxel on Day 8 and/or Day 15, the study visit and assessments for that specific day can be omitted.",
        "footnoteId": "fn_1",
        "structuredCondition": "if(subject.discontinued('paclitaxel', ['Day 8', 'Day 15']), omit_visit(current))",
        "appliesToActivityIds": [
          "All assessments"
        ],
        "sourceText": "a. If a subject discontinues paclitaxel on Day 8 and/or Day 15, the study visit and assessments for "
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "b. Must be performed prior to the initiation of any screening or study-specific procedures.",
        "footnoteId": "fn_2",
        "structuredCondition": "sequence.first(informed_consent)",
        "appliesToActivityIds": [
          "Screening procedures",
          "Study-specific procedures"
        ],
        "sourceText": "b. Must be performed prior to the initiation of any screening or study-specific procedures."
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "c. Height will be recorded at Screening Visit only.",
        "footnoteId": "fn_3",
        "structuredCondition": "frequency.once('Screening')",
        "appliesToActivityIds": [
          "Height"
        ],
        "sourceText": "c. Height will be recorded at Screening Visit only."
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_before",
        "text": "d. Physical exam not required, if performed within 7 days prior to C1D-2, unless clinically indicated.",
        "footnoteId": "fn_4",
        "structuredCondition": "if(last_performed('Physical exam') > P7D || clinical_indication == true, perform('Physical exam'))",
        "appliesToActivityIds": [
          "Physical exam"
        ],
        "sourceText": "d. Physical exam not required, if performed within 7 days prior to C1D-2, unless clinically indicate"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "timing_before",
        "text": "e. ECG must be obtained one hour after dosing with veliparib/placebo and prior to the paclitaxel or carboplatin infusions.",
        "footnoteId": "fn_5",
        "structuredCondition": "timing.after(dosing.veliparib_placebo, PT1H) && timing.before(infusion.paclitaxel_carboplatin)",
        "appliesToActivityIds": [
          "ECG"
        ],
        "sourceText": "e. ECG must be obtained one hour after dosing with veliparib/placebo and prior to the paclitaxel or "
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_before",
        "text": "f. Pregnancy tests must be completed and confirmed as not indicative of pregnancy prior to randomization (within 24 hours).",
        "footnoteId": "fn_6",
        "structuredCondition": "timing.before(randomization, PT24H) && result == negative",
        "appliesToActivityIds": [
          "Pregnancy tests"
        ],
        "timingConstraint": "PT24H",
        "sourceText": "f. Pregnancy tests must be completed and confirmed as not indicative of pregnancy prior to randomiza"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "g. Refer to Table 4 for detailed list of tests to be performed and frequency.",
        "footnoteId": "fn_7",
        "structuredCondition": "reference(Table_4)",
        "appliesToActivityIds": [
          "All tests"
        ],
        "sourceText": "g. Refer to Table 4 for detailed list of tests to be performed and frequency."
      },
      {
        "id": "fn_cond_8",
        "conditionType": "timing_before",
        "text": "h. For Day 1 visits, study samples for central laboratory analysis may be performed within 72 hours prior to dosing.",
        "footnoteId": "fn_8",
        "structuredCondition": "timing.before(dosing., PT72M)",
        "appliesToActivityIds": [
          "Central laboratory analysis"
        ],
        "timingConstraint": "PT72H",
        "sourceText": "h. For Day 1 visits, study samples for central laboratory analysis may be performed within 72 hours "
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_before",
        "text": "i. For Screening labs performed greater than 7 days prior to C1D-2, hematology/chemistry should be split.",
        "footnoteId": "fn_9",
        "structuredCondition": "if(timing.since(screening_labs, C1D-2) > P7D, split(hematology, chemistry))",
        "appliesToActivityIds": [
          "Hematology",
          "Chemistry"
        ],
        "sourceText": "i. For Screening labs performed greater than 7 days prior to C1D-2, hematology/chemistry should be s"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "timing_before",
        "text": "j. For subjects on prophylactic or therapeutic anticoagulation with warfarin, INR should be monitored before each treatment.",
        "footnoteId": "fn_10",
        "structuredCondition": "if(subject.medication == 'warfarin', timing.before(treatment))",
        "appliesToActivityIds": [
          "INR monitoring"
        ],
        "sourceText": "j. For subjects on prophylactic or therapeutic anticoagulation with warfarin, INR should be monitore"
      },
      {
        "id": "fn_cond_11",
        "conditionType": "timing_before",
        "text": "k. BRCA1 and BRCA2 germline mutation testing will be collected on all subjects even if Sponsor core laboratory testing was performed prior to screening.",
        "footnoteId": "fn_11",
        "sourceText": "k. BRCA1 and BRCA2 germline mutation testing will be collected on all subjects even if Sponsor core "
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "l. Tumor assessments to support evidence of PD for PFS endpoint collected every 9 weeks until PD.",
        "footnoteId": "fn_12",
        "sourceText": "l. Tumor assessments to support evidence of PD for PFS endpoint collected every 9 weeks until PD."
      },
      {
        "id": "fn_cond_13",
        "conditionType": "timing_before",
        "text": "Note: Study procedures (excluding labs and tumor assessments) may be performed four (4) business days prior to or after the scheduled study visit date.",
        "footnoteId": "fn_13",
        "sourceText": "Note: Study procedures (excluding labs and tumor assessments) may be performed four (4) business day"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Progression-free Survival (PFS)",
        "endpointType": "Primary",
        "inputs": [
          "Date of randomization",
          "Date of disease progression (RECIST 1.1)",
          "Date of death"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until progression or death; assessments every 9 weeks (initially) then 12-24 weeks"
        },
        "algorithm": "min(Date of disease progression, Date of death) - Date of randomization",
        "successCriteria": "Statistically significant increase in days compared to placebo (Hazard Ratio 0.69 target)",
        "sourceText": "Progression-Free Survival (PFS): will be defined as the number of days from the date the subject is randomized to the date the subject experiences disease progression per RECIST (version 1.1) and surv"
      },
      {
        "id": "ep_2",
        "name": "Secondary: Overall Survival (OS)",
        "endpointType": "Secondary",
        "inputs": [
          "Date of randomization",
          "Date of death"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until death or study termination"
        },
        "algorithm": "Date of death - Date of randomization",
        "successCriteria": "Statistically significant improvement in survival time",
        "sourceText": "Overall Survival (OS): will be evaluated according to survival information... until the endpoint of death, the subject is lost to follow-up or until the study termination by AbbVie."
      },
      {
        "id": "ep_3",
        "name": "Secondary: Objective Response Rate (ORR)",
        "endpointType": "Secondary",
        "inputs": [
          "Complete Response (CR) status",
          "Partial Response (PR) status",
          "Total number of subjects"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "9-week intervals (initially) then 12-24 weeks"
        },
        "algorithm": "(Count of subjects with CR + Count of subjects with PR) / Total subjects",
        "successCriteria": "Higher proportion of responders in veliparib arm vs placebo",
        "sourceText": "Objective Response Rate (ORR)... will be evaluated according to progression per RECIST (version 1.1)."
      },
      {
        "id": "ep_4",
        "name": "Secondary: Clinical Benefit Rate (CBR)",
        "endpointType": "Secondary",
        "inputs": [
          "RECIST 1.1 response status",
          "Duration of Stable Disease (SD)"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "9-week intervals (initially) then 12-24 weeks"
        },
        "algorithm": "(Count of subjects with CR + PR + SD) / Total subjects",
        "successCriteria": "Higher proportion of subjects with clinical benefit in veliparib arm",
        "sourceText": "Clinical benefit rate (CBR)... will be evaluated according to progression per RECIST (version 1.1)."
      },
      {
        "id": "ep_5",
        "name": "Secondary: PFS2",
        "endpointType": "Secondary",
        "inputs": [
          "Date of randomization",
          "Date of second disease progression",
          "Date of death"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until second progression or death; monitored at two-month intervals post-study"
        },
        "algorithm": "min(Date of second progression, Date of death) - Date of randomization",
        "successCriteria": "Improvement in time to second progression or death",
        "sourceText": "PFS2: will be evaluated according to survival information and post treatment information (includes dates of therapy and response per RECIST 1.1) collected at two-month intervals."
      },
      {
        "id": "ep_6",
        "name": "Tertiary: Duration of Overall Response (DOR)",
        "endpointType": "Secondary",
        "inputs": [
          "Date of first objective response (CR or PR)",
          "Date of disease progression"
        ],
        "timeWindow": {
          "reference": "First response",
          "duration": "Until progression"
        },
        "algorithm": "Date of disease progression - Date of first objective response",
        "successCriteria": "Longer duration of response in veliparib arm",
        "sourceText": "Duration of Overall Response (DOR): will be evaluated according to progression per RECIST (version 1.1)."
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Progression-Free Survival (PFS)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Randomization",
          "Date of Disease Progression",
          "Date of Death"
        ],
        "derivationRule": "The time from the date of randomization to the date of earliest objective disease progression (per RECIST 1.1) or death from any cause.",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "Continuous from randomization until event or censoring",
        "imputationRule": "Censoring rules per RECIST 1.1 guidelines for subjects without event",
        "unit": "Days/Months"
      },
      {
        "id": "dv_2",
        "name": "Overall Survival (OS)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Randomization",
          "Date of Death"
        ],
        "derivationRule": "The time from the date of randomization to the date of death from any cause.",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "Continuous from randomization until death or censoring",
        "imputationRule": "Censored at the date the subject was last known to be alive",
        "unit": "Days/Months"
      },
      {
        "id": "dv_3",
        "name": "Clinical Benefit Rate (CBR)",
        "variableType": "Categorical",
        "sourceVariables": [
          "RECIST 1.1 Response",
          "Duration of Stable Disease"
        ],
        "derivationRule": "Proportion of subjects with a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) of a specific minimum duration.",
        "baselineDefinition": "Presence of measurable or non-measurable disease at baseline",
        "baselineVisit": "Screening/Baseline",
        "analysisWindow": "Duration of study treatment",
        "imputationRule": "Non-responder imputation for missing assessments",
        "unit": "%"
      },
      {
        "id": "dv_4",
        "name": "Objective Response Rate (ORR)",
        "variableType": "Categorical",
        "sourceVariables": [
          "RECIST 1.1 Response"
        ],
        "derivationRule": "Proportion of subjects with a best overall response of Complete Response (CR) or Partial Response (PR).",
        "baselineDefinition": "Presence of measurable disease at baseline",
        "baselineVisit": "Screening/Baseline",
        "analysisWindow": "Duration of study treatment",
        "imputationRule": "Non-responder imputation for missing assessments",
        "unit": "%"
      },
      {
        "id": "dv_5",
        "name": "PFS2",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Randomization",
          "Date of Second Progression",
          "Date of Death"
        ],
        "derivationRule": "The time from the date of randomization to the date of second objective disease progression or death from any cause.",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "Continuous from randomization until second event",
        "imputationRule": "Censoring rules per protocol for subjects without second event",
        "unit": "Days/Months"
      },
      {
        "id": "dv_6",
        "name": "Duration of Response (DOR)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of First Response",
          "Date of Disease Progression",
          "Date of Death"
        ],
        "derivationRule": "The time from the first documented response (CR or PR) to the date of earliest objective disease progression or death.",
        "baselineDefinition": "Date of first documented response",
        "baselineVisit": "Post-baseline",
        "analysisWindow": "From first response until event",
        "imputationRule": "Censored at last tumor assessment for subjects without progression",
        "unit": "Days/Months"
      },
      {
        "id": "dv_7",
        "name": "Change in ECOG Performance Status",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "ECOG Score"
        ],
        "derivationRule": "Post-baseline ECOG score - Baseline ECOG score",
        "baselineDefinition": "Last non-missing value prior to first dose of study drug",
        "baselineVisit": "Day 1 or Screening",
        "analysisWindow": "Scheduled assessment visits",
        "imputationRule": "Last Observation Carried Forward (LOCF) or as specified in SAP",
        "unit": "Score"
      },
      {
        "id": "dv_8",
        "name": "Change in QoL Indices",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "QoL Questionnaire Scores"
        ],
        "derivationRule": "Post-baseline QoL score - Baseline QoL score",
        "baselineDefinition": "Last non-missing value prior to first dose of study drug",
        "baselineVisit": "Day 1",
        "analysisWindow": "Scheduled assessment visits",
        "imputationRule": "Missing items handled per specific QoL instrument scoring manual",
        "unit": "Score"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Randomization",
        "Treatment Combination Phase",
        "Treatment Monotherapy Phase",
        "Post Treatment Follow Up",
        "Survival Follow Up",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Randomization",
          "trigger": "Progress to Randomization"
        },
        {
          "fromState": "Randomization",
          "toState": "Treatment Combination Phase",
          "trigger": "Progress to Treatment Combination Phase"
        },
        {
          "fromState": "Treatment Combination Phase",
          "toState": "Treatment Monotherapy Phase",
          "trigger": "Progress to Treatment Monotherapy Phase"
        },
        {
          "fromState": "Treatment Monotherapy Phase",
          "toState": "Post Treatment Follow Up",
          "trigger": "Progress to Post Treatment Follow Up"
        },
        {
          "fromState": "Post Treatment Follow Up",
          "toState": "Survival Follow Up",
          "trigger": "Progress to Survival Follow Up"
        },
        {
          "fromState": "Treatment Combination Phase",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Treatment Monotherapy Phase",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Post Treatment Follow Up",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Randomization": "RANDOMIZATION",
        "Treatment Combination Phase": "TREATMENT_COMBINATION_PHASE",
        "Treatment Monotherapy Phase": "TREATMENT_MONOTHERAPY_PHASE",
        "Post Treatment Follow Up": "POST_TREATMENT_FOLLOW_UP",
        "Survival Follow Up": "SURVIVAL_FOLLOW_UP",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Veliparib",
        "frequency": "BID",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 120.0,
            "unit": "mg"
          },
          {
            "amount": 80.0,
            "unit": "mg"
          }
        ],
        "sourceText": "mor biopsy. Approximately 200 research sites will participate. Subjects will be randomized in a 2:1 ratio to one of the two treatment arms with a total of approximately 500 subjects randomized. Velipa"
      },
      {
        "id": "dosing_2",
        "treatmentName": "and Paclitaxel",
        "frequency": "BID",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 80.0,
            "unit": "mg"
          },
          {
            "amount": 120.0,
            "unit": "mg"
          }
        ],
        "sourceText": "io to one of the two treatment arms with a total of approximately 500 subjects randomized. Veliparib 120 mg/placebo BID will be dosed Days –2 through 5 with carboplatin AUC 6 administered on Day 1 and"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "Veliparib (ABT-888)",
        "frequency": "BID",
        "route": "Oral",
        "startDay": 1,
        "durationDescription": "Until disease progression or unacceptable toxicity",
        "doseModifications": [
          "Dose adjustment for multiple cycles without uncontrolled adverse events",
          "Guidelines on when chemotherapy can begin based on hematologic blood counts"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Placebo",
        "frequency": "BID",
        "route": "Oral",
        "startDay": 1,
        "durationDescription": "Until disease progression or unacceptable toxicity"
      },
      {
        "id": "dosing_llm_3",
        "treatmentName": "Carboplatin",
        "frequency": "Q3W",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Until disease progression or unacceptable toxicity",
        "doseModifications": [
          "Guidelines on when chemotherapy can begin based on hematologic blood counts"
        ]
      },
      {
        "id": "dosing_llm_4",
        "treatmentName": "Paclitaxel",
        "frequency": "QW",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Until disease progression or unacceptable toxicity",
        "doseModifications": [
          "Guidelines on when chemotherapy can begin based on hematologic blood counts"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_3",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "were performed at screening and then every 9 weeks from C1D-2 until tumor progression to determine the extent of tumor burden per RECIST 1.1. Following the primary analysis and implementation of Proto"
      },
      {
        "id": "visit_llm_2",
        "visitName": "Cycle 1 Day -2",
        "targetDay": -2,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 2,
        "epoch": "Treatment"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "and the safety profile of veliparib in combination with carboplatin and paclitaxel was acceptable. ●"
      },
      {
        "id": "visit_4",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "baseline brain MRI or contrast CT is only required in subjects with CNS lesions at baseline; in all other subjects, CNS imaging will be obtained as clinically indicated based upon symptoms indicative "
      },
      {
        "id": "visit_llm_7",
        "visitName": "Final Visit",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "Post-Treatment"
      },
      {
        "id": "visit_6",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 28,
        "windowAfter": 28,
        "isRequired": true,
        "visitNumber": 6,
        "epoch": "Treatment",
        "sourceText": "Subjects should have a brain MRI within 28 days of randomization to confirm the absence of CNS metastases. Contrast CT is acceptable for subjects who are unable to undergo a brain MRI. !"
      },
      {
        "id": "visit_8",
        "visitName": "Day 3",
        "targetDay": 3,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "paclitaxel 200 mg/m2 administered on Day 3 of a 21-day cycle with 2 out of 6 subjects developing protocol-defined dose limiting toxicities (DLTs) at this dose. The first DLT was grade 3 nausea lasting"
      },
      {
        "id": "visit_14",
        "visitName": "Day 5",
        "targetDay": 5,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "sourceText": "veliparib/placebo for dosing through Day 5 and additional study drug for Cycle 2 Days –2 and –1. For subsequent cycles, subjects will receive veliparib/placebo for Days 1 – 5 of the current cycle and "
      },
      {
        "id": "visit_11",
        "visitName": "Week 2",
        "targetDay": 8,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "targetWeek": 2,
        "sourceText": "Week 2 6 7"
      },
      {
        "id": "visit_12",
        "visitName": "Week 3",
        "targetDay": 15,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "targetWeek": 3,
        "sourceText": "Week 3 13 14"
      },
      {
        "id": "visit_13",
        "visitName": "Day 21",
        "targetDay": 21,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "sourceText": "continue through Day 21 of a 21-day cycle. For subjects who have been receiving single- agent veliparib/placebo at a stable dose without adjustment for multiple cycles and who have no ongoing study dr"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Cycle 2 Day 1",
        "targetDay": 22,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 4,
        "targetWeek": 4,
        "epoch": "Treatment"
      },
      {
        "id": "visit_llm_8",
        "visitName": "30-Day Follow-Up Visit",
        "targetDay": 30,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 8,
        "epoch": "Post-Treatment"
      },
      {
        "id": "visit_llm_9",
        "visitName": "Survival Follow-Up (Every 2 Months)",
        "targetDay": 60,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 9,
        "targetWeek": 8,
        "epoch": "Post-Treatment"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Tumor Assessment (Every 9 Weeks)",
        "targetDay": 61,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 6,
        "targetWeek": 9,
        "epoch": "Treatment"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Cycle 4 Day 1",
        "targetDay": 64,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 10,
        "epoch": "Treatment"
      },
      {
        "id": "visit_9",
        "visitName": "Week 24",
        "targetDay": 162,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 17,
        "targetWeek": 24,
        "sourceText": "rate (CBR) through the end of Week 24, objective response rate (ORR) and PFS2 in subjects treated with veliparib in combination with carboplatin and paclitaxel versus placebo in combination with carbo"
      },
      {
        "id": "visit_2",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 18,
        "sourceText": "assessment. Also, to ensure that survival follow-up is the same for all subjects who have discontinued therapy, and to remove the requirement of tumor assessment at Final Visit in subjects without a t"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "2:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_llm_1",
          "name": "Hormone receptor status",
          "categories": [
            "Estrogen receptor (ER) and/or progesterone receptor (PgR) positive",
            "ER/PgR negative"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Prior platinum therapy",
          "categories": [
            "Yes",
            "No"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_3",
          "name": "CNS metastases",
          "categories": [
            "Yes",
            "No"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Veliparib\nM12-914 Protocol Amendment 4\nEudraCT 2014-000345-70\n6\n1.2\nSynopsis\nAbbVie\nProtocol Number:  M12-914\nName of Study Drug:  Veliparib (ABT-888)\nPhase of Development:  Phase 3\nName of Active Ing"
    }
  }
}